Clinical Scorecard: Thrombotic Microangiopathy Associated with Carfilzomib: A Frequently Overlooked Range of Conditions from Microangiopathic Hemolysis to Asymptomatic TMA

At a Glance

Key Highlights

• 35.5% of carfilzomib-treated patients developed MAHA; 6.5% progressed to severe TMA
• MAHA episodes ranged from low-grade, often asymptomatic, to severe TMA with end organ damage, especially acute kidney injury
• Older age was significantly associated with development of MAHA/TMA; episodes could occur between cycle 2 and 19

Guideline-Based Recommendations

Diagnosis

• Identify MAHA by presence of schistocytes on peripheral blood film, anemia, thrombocytopenia with >25% platelet drop, and elevated LDH
• Define TMA as MAHA plus end organ dysfunction, particularly acute kidney injury per KDIGO criteria
• Exclude confounders such as tumor lysis syndrome and progressive myeloma by correlating with disease markers

Management

• Continue carfilzomib cautiously in low-grade MAHA without immediate complications
• Discontinue carfilzomib in severe TMA cases
• Consider eculizumab therapy early in severe TMA presentations to improve hematologic and organ outcomes

Monitoring & Follow-up

• Regular monitoring of blood counts, LDH, peripheral blood films for schistocytes, and renal function during carfilzomib therapy
• Assess for signs of hemolysis and kidney injury especially after cycle 2 onwards
• Monitor cardiac function in severe TMA cases due to possible cardiac involvement

Risks

• Older age increases risk of MAHA/TMA
• Concurrent infections may precipitate or worsen MAHA/TMA episodes
• Pre-existing renal impairment may complicate TMA outcomes

Patient & Prescribing Data

31 patients with relapsed multiple myeloma treated with carfilzomib (median age 67, diverse ethnicities, median 3 prior therapies)

Most patients received carfilzomib 56 mg/m2 twice weekly with dexamethasone; low-grade MAHA episodes often did not require treatment interruption; severe TMA required cessation and complement inhibition

Clinical Best Practices

• Apply strict diagnostic criteria for MAHA and TMA to detect subclinical cases
• Exclude alternative causes of hemolysis and kidney injury by correlating with myeloma disease markers
• Early recognition and treatment of severe TMA with eculizumab can improve outcomes
• Continue carfilzomib cautiously in low-grade MAHA with close monitoring
• Consider patient age and infection status as risk factors when monitoring for TMA

References

• Carfilzomib-induced TMA and complement dysregulation
• KDIGO guidelines for acute kidney injury
• Eculizumab use in drug-induced TMA